Oncology Times


Oncology Times is pleased to report on the latest groundbreaking research presented at the AACR 2018 Annual Meeting, Chicago, IL. 

Potent & Selective TKI Shows Potential With RET-Altered Cancer Patients

Preliminary proof-of-concept data were presented from an ongoing phase I clinical trial evaluating the use of the next-generation, RET tyrosine kinase inhibitor BLU-667 at the AACR 2018 Annual Meeting.

Read More


Mutations Confer Resistance to Hormone Therapy in Metastatic Breast Cancer

Acquired HER2 mutations confer resistance to hormone therapy in some ER-positive metastatic breast cancer patients. 

Read More


Immunotherapy Shows Promise Among Lung Cancer Patients

Advances in immunotherapy continue to confirm the power of harnessing the immune system in the treatment of cancer patients.

Read More


Prior Chemotherapies Impair CAR T-Cell Production

Prior chemotherapies may impair the ability to develop effective chimeric antigen receptor (CAR) T cells to treat children with solid tumors

Read More


Pembrolizumab Shows Reduced Risk for Recurrence in Completely Resected Stage III Melanoma

A 1-year course of 18 doses of adjuvant pembrolizumab was shown to significantly reduce the risk of recurrence for stage III melanoma patients that were at high risk of recurrence after surgery.

Read More


Vulnerable Populations Lack Information About Clinical Trials & Biobanking

People who experience cancer health disparities are interested in participating in clinical trials or submitting samples to biobanks if they receive this information from a trusted physician.

Read More


Risk of Cancers Increased Among Children With Non-Chromosomal Birth Defects

A recent study suggests that children with non-chromosomal birth defects had a significantly higher risk of developing childhood cancer than those who did not have birth defects.

Read More


Prior Chlamydia Infection Doubles Risk of Ovarian Cancer

Prior infection with the sexually transmitted disease chlamydia may double the risk of ovarian cancer, suggesting a potential way to reduce the risk of ovarian cancer through targeted treatment of chlamydia infections, according to a new study.

Read More